Investment Set To Rise, Non-COVID R&D To Normalize As Korean Pharma Looks Ahead To 2022
Last Year Marked By Solid R&D, Financing Progress
Scrip takes a look back at the milestone events in the South Korean pharma and biotech industry in 2021 and ahead at what's in store for the coming year, which has kicked off with speculation around a major potential M&A deal.
